Combining 153Sm-lexidronam and docetaxel for the treatment of patients with hormone-refractory prostate cancer: First experience

Cancer Biotherapy and Radiopharmaceuticals

Volumn 23, Issue 5, 2008, Pages 609-618

  Suttmann, Henrik ^a   Grgic, Aleksandar ^a   Lehmann, Jan ^a   Zwergel, Ulrike ^a   Kamradt, Jörn ^a   Gouverneur, Eric ^a   Pinkert, Jörg ^b   Stöckle, Michael ^a   Kirsch, Carl Martin ^a   Nestle, Ursula ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b BAYER AG   (Germany)

Author keywords

Bone; Metastases; Prostate cancer; Samarium 153 lexidronam; Therapy

Indexed keywords

DOCETAXEL; LEXIDRONAM SAMARIUM SM 153; PROSTATE SPECIFIC ANTIGEN; ANALGESIC AGENT; ANTINEOPLASTIC AGENT; ORGANOMETALLIC COMPOUND; ORGANOPHOSPHORUS COMPOUND; RADIOISOTOPE; SAMARIUM ETHYLENEDIAMINETETRAMETHYLENEPHOSPHONATE; TAXOID; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL ARTICLE; FEASIBILITY STUDY; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; PAIN ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; SEPSIS; SIDE EFFECT; VISUAL ANALOG SCALE; BIOSYNTHESIS; BODY WEIGHT; METASTASIS; MIDDLE AGED; PROSTATE TUMOR; TIME; TREATMENT OUTCOME;

AGED; ANALGESICS, NON-NARCOTIC; ANTINEOPLASTIC AGENTS; BODY WEIGHT; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOISOTOPES; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 55849106644     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2008.0487     Document Type: Article

References (30)

1. McCready VR, O'Sullivan JM. Future directions for unsealed source radionuclide therapy for bone metastases. Eur J Nucl Med Mol Imaging 2002;29:1271.
2. Aus G, Abbou CC, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol 2005;48:546.
3. Saarto T, Janes R, Tenhunen M, et al. Palliative radiotherapy in the treatment of skeletal metastases. Eur J Pain 2002;6:323.
4. Pecher C. Biological investigations with radioactive calcium and strontium: Preliminary report on the use of radioactive strontium in the treatment of bone cancer. Univ Calif Pub Pharmacol 1942;11:117.
5. Friedell HL, Storaasli JP. The use of radioactive phosphorus in the treatment of carcinoma of the breast with widespread metastases to the bone. Am J Roentgenol Rad Ther 1950;64:559.
6. Bauman G, Charette M, Reid R, et al. Radiopharmaceuticals for the palliation of painful bone metastasis - a systemic review. Radiother Oncol 2005;75:258.
7. Maxon H, Schroder L, Hertzberg V, et al. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: Results of a double-blind crossover comparison with placebo. J Nucl Med 1991;32:1877.
8. Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: A double-blind placebo-controlled clinical trial. J Clin Oncol 1998;16:1574.
9. Sartor O, Reid RH, Hoskin PJ, et al. Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004;63:940.
10. Porter AT, McEwan AJ, Powe JE, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993;25:805.
11. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879.
12. Wang RF, Zhang CL, Zhu SL, et al. A comparative study of samarium-153-ethylenediaminetetramethylene phosphonic acid with pamidronate disodium in the treatment of patients with painful metastatic bone cancer. Med Princ Pract 2003;12:97.
13. Turner J, Claringbold P, Hetherington E, et al. A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases. J Clin Oncol 1989;7:1926.
14. Resche I, Chatal JF, Pecking A, et al. A dose-controlled study of 153Sm-ethylenediaminetetramethylene phosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer 1997;33:1583.
15. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502.
16. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513.
17. Shelley M, Harrison C, Coles B, et al. Chemotherapy for hormone-refractory prostate cancer. Cochr Database Syst Rev 2006;4:CD005247.
18. Nabell L, Spencer S. Docetaxel with concurrent radiotherapy in head and neck cancer. Semin Oncol 2003;30:89.
19. Vokes EE, Choy H, Gandara D, et al. Adjuvant and neoadjuvant treatments for NSCLC. Lung Cancer 2002;38(Suppl 4):29.
20. Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: A randomised phase II trial. Lancet 2001;357:336.
21. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17:3461.
22. 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging 2007;34:1023.
23. Basch EM, Somerfield MR, Beer TM, et al. American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. J Clin Oncol 2007;25:5313.
24. Widmark A, Modig H, Johansson M, et al. TAXSAM: A new chemo-radiation regimen for bone metastases in hormone-refractory prostate cancer [abstr. 221]. 2006 Prostate Cancer Symposium, San Francisco, CA, February 24-26, 2006.
25. Fizazi K, Beuzeboc P, Lumbroso J, et al. A phase II trial of maintenance docetaxel and samarium in patients with castration-refractory bone metastases from prostate cancer with response or stabilization after induction docetaxel-estramustine: Preliminary results [abstr. 223]. 2006 Prostate Cancer Symposium, San Francisco, CA, February 24-26, 2006.
26. Dolezal J, Vizda J, Odrazka K. Prospective evaluation of samarium-153-EDTMP radionuclide treatment for bone metastases in patients with hormone-refractory prostate cancer. Urol Int 2007;78:50.
27. Alberts AS, Smit BJ, Louw WK, et al. Dose response relationship and multiple dose efficacy and toxicity of samarium-153-EDTMP in metastatic cancer to bone. Radiother Oncol 1997;43:175.
28. Massard C, Laplanche A, Beuzeboc P, et al. A phase II trial of docetaxel and samarium153-EDTMP in patients (pts) with bone metastases from castration-refractory prostate cancer (CRPC) with response or stabilization after induction docetaxel-estramustine [abstr. 227]. 2007 Prostate Cancer Symposium, Orlando, FL, February 22-24, 2007.
29. Shiraishi J, Li Q, Appelbaum D, et al. Development of a computer-aided diagnostic scheme for detection of interval changes in successive whole-body bone scans. Med Phys 2007;34:25.
30. Hirano D, Minei S, Sugimoto S, et al. Implications of circulating chromogranin A in prostate cancer. Scand J Urol Nephrol 2007;41:297.